

- Sec.
 350c. Maintenance and inspection of records.
 350d. Registration of food facilities.
 350e. Sanitary transportation practices.
 350f. Reportable food registry.
 350g. Hazard analysis and risk-based preventive controls.
 350h. Standards for produce safety.
 350i. Protection against intentional adulteration.
 350j. Targeting of inspection resources for domestic facilities, foreign facilities, and ports of entry; annual report.
 350k. Laboratory accreditation for analyses of foods.
 350l. Mandatory recall authority.
 350l-1. Annual report to Congress.

SUBCHAPTER V—DRUGS AND DEVICES

PART A—DRUGS AND DEVICES

351. Adulterated drugs and devices.
 352. Misbranded drugs and devices.
 353. Exemptions and consideration for certain drugs, devices, and biological products.
 353a. Pharmacy compounding.
 353b. Prereview of television advertisements.
 354. Veterinary feed directive drugs.
 355. New drugs.
 355-1. Risk evaluation and mitigation strategies.
 355a. Pediatric studies of drugs.
 355b. Adverse-event reporting.
 355c. Research into pediatric uses for drugs and biological products.
 355d. Internal committee for review of pediatric plans, assessments, deferrals, and waivers.
 355e. Pharmaceutical security.
 356. Fast track products.
 356-1. Accelerated approval of priority countermeasures.
 356a. Manufacturing changes.
 356b. Reports of postmarketing studies.
 356c. Discontinuance of life saving product.
 357. Repealed.
 358. Authority to designate official names.
 359. Nonapplicability of subchapter to cosmetics.
 360. Registration of producers of drugs or devices.
 360a. Clinical trial guidance for antibiotic drugs.
 360b. New animal drugs.
 360c. Classification of devices intended for human use.
 360d. Performance standards.
 360e. Premarket approval.
 360e-1. Pediatric uses of devices.
 360f. Banned devices.
 360g. Judicial review.
 360h. Notification and other remedies.
 360i. Records and reports on devices.
 360j. General provisions respecting control of devices intended for human use.
 360k. State and local requirements respecting devices.
 360l. Postmarket surveillance.
 360m. Accredited persons.
 360n. Priority review to encourage treatments for tropical diseases.

PART B—DRUGS FOR RARE DISEASES OR CONDITIONS

- 360aa. Recommendations for investigations of drugs for rare diseases or conditions.
 360bb. Designation of drugs for rare diseases or conditions.
 360cc. Protection for drugs for rare diseases or conditions.
 360dd. Open protocols for investigations of drugs for rare diseases or conditions.
 360ee. Grants and contracts for development of drugs for rare diseases and conditions.

PART C—ELECTRONIC PRODUCT RADIATION CONTROL

- 360hh. Definitions.

- Sec.
 360ii. Program of control.
 360jj. Studies by Secretary.
 360kk. Performance standards for electronic products.
 360ll. Notification of defects in and repair or replacement of electronic products.
 360mm. Imports.
 360nn. Inspection, records, and reports.
 360oo. Prohibited acts.
 360pp. Enforcement.
 360qq. Repealed.
 360rr. Federal-State cooperation.
 360ss. State standards.

PART D—DISSEMINATION OF TREATMENT INFORMATION

360aaa to 360aaa-6. Omitted

PART E—GENERAL PROVISIONS RELATING TO DRUGS AND DEVICES

- 360bbb. Expanded access to unapproved therapies and diagnostics.
 360bbb-1. Dispute resolution.
 360bbb-2. Classification of products.
 360bbb-3. Authorization for medical products for use in emergencies.
 360bbb-4. Technical assistance.
 360bbb-5. Critical Path Public-Private Partnerships.
 360bbb-6. Risk communication.

PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES

- 360ccc. Conditional approval of new animal drugs for minor use and minor species.
 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species.
 360ccc-2. Designated new animal drugs for minor use or minor species.

SUBCHAPTER VI—COSMETICS

361. Adulterated cosmetics.
 362. Misbranded cosmetics.
 363. Regulations making exemptions.
 364. Repealed.

SUBCHAPTER VII—GENERAL AUTHORITY

PART A—GENERAL ADMINISTRATIVE PROVISIONS

371. Regulations and hearings.
 372. Examinations and investigations.
 372a. Transferred.
 373. Records.
 374. Inspection.
 374a. Inspections relating to food allergens.
 375. Publicity.
 376. Examination of sea food on request of packer; marking food with results; fees; penalties.
 377. Revision of United States Pharmacopoeia; development of analysis and mechanical and physical tests.
 378. Advertising of foods.
 379. Confidential information.
 379a. Presumption of existence of jurisdiction.
 379b. Consolidated administrative and laboratory facility.
 379c. Transferred.
 379d. Automation of Food and Drug Administration.
 379d-1. Conflicts of interest.
 379d-2. Policy on the review and clearance of scientific articles published by FDA employees.

PART B—COLORS

- 379e. Listing and certification of color additives for foods, drugs, devices, and cosmetics.

PART C—FEES

SUBPART 1—FREEDOM OF INFORMATION FEES

- 379f. Recovery and retention of fees for freedom of information requests.

- Sec. SUBPART 2—FEES RELATING TO DRUGS
- 379g. Definitions.
- 379h. Authority to assess and use drug fees.
- 379h-1. Fees relating to advisory review of prescription-drug television advertising.
- 379h-2. Reauthorization; reporting requirements.
- SUBPART 3—FEES RELATING TO DEVICES
- 379i. Definitions.
- 379j. Authority to assess and use device fees.
- 379j-1. Reauthorization; reporting requirements.
- SUBPART 4—FEES RELATING TO ANIMAL DRUGS
- 379j-11. Definitions.
- 379j-12. Authority to assess and use animal drug fees.
- 379j-13. Reauthorization; reporting requirements.
- SUBPART 5—FEES RELATING TO GENERIC NEW ANIMAL DRUGS
- 379j-21. Authority to assess and use generic new animal drug fees.
- 379j-22. Reauthorization; reporting requirements.
- SUBPART 6—FEES RELATED TO FOOD
- 379j-31. Authority to collect and use fees.
- PART D—INFORMATION AND EDUCATION
- 379k. Information system.
- 379l. Education.
- PART E—ENVIRONMENTAL IMPACT REVIEW
- 379o. Environmental impact.
- PART F—NATIONAL UNIFORMITY FOR NONPRESCRIPTION DRUGS AND PREEMPTION FOR LABELING OR PACKAGING OF COSMETICS
- 379r. National uniformity for nonprescription drugs.
- 379s. Preemption for labeling or packaging of cosmetics.
- PART G—SAFETY REPORTS
- 379v. Safety report disclaimers.
- PART H—SERIOUS ADVERSE EVENT REPORTS
- 379aa. Serious adverse event reporting for nonprescription drugs.
- 379aa-1. Serious adverse event reporting for dietary supplements.
- PART I—REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION
- 379dd. Establishment and functions of the Foundation.
- 379dd-1. Location of Foundation.
- 379dd-2. Activities of the Food and Drug Administration.
- SUBCHAPTER VIII—IMPORTS AND EXPORTS
381. Imports and exports.
382. Exports of certain unapproved products.
383. Office of International Relations.
384. Importation of prescription drugs.
- 384a. Foreign supplier verification program.
- 384b. Voluntary qualified importer program.
- 384c. Inspection of foreign food facilities.
- 384d. Accreditation of third-party auditors.
- SUBCHAPTER IX—TOBACCO PRODUCTS
387. Definitions.
- 387a. FDA authority over tobacco products.
- 387a-1. Final rule.
- 387b. Adulterated tobacco products.
- 387c. Misbranded tobacco products.
- 387d. Submission of health information to the Secretary.

- Sec. 387e. Annual registration.
- 387f. General provisions respecting control of tobacco products.
- 387f-1. Enforcement action plan for advertising and promotion restrictions.
- 387g. Tobacco product standards.
- 387h. Notification and other remedies.
- 387i. Records and reports on tobacco products.
- 387j. Application for review of certain tobacco products.
- 387k. Modified risk tobacco products.
- 387l. Judicial review.
- 387m. Equal treatment of retail outlets.
- 387n. Jurisdiction of and coordination with the Federal Trade Commission.
- 387o. Regulation requirement.
- 387p. Preservation of State and local authority.
- 387q. Tobacco Products Scientific Advisory Committee.
- 387r. Drug products used to treat tobacco dependence.
- 387s. User fees.
- 387t. Labeling, recordkeeping, records inspection.
- 387u. Studies of progress and effectiveness.

SUBCHAPTER X—MISCELLANEOUS

391. Separability clause.
392. Exemption of meats and meat food products.
393. Food and Drug Administration.
- 393a. Office of Pediatric Therapeutics.
394. Scientific review groups.
395. Loan repayment program.
396. Practice of medicine.
397. Contracts for expert review.
398. Notices to States regarding imported food.
399. Grants to enhance food safety.
- 399a. Office of the Chief Scientist.
- 399b. Office of Women's Health.
- 399c. Improving the training of State, local, territorial, and tribal food safety officials.
- 399d. Employee protections.

SUBCHAPTER I—SHORT TITLE

§ 301. Short title

This chapter may be cited as the Federal Food, Drug, and Cosmetic Act.

(June 25, 1938, ch. 675, § 1, 52 Stat. 1040.)

EFFECTIVE DATE; POSTPONEMENT IN CERTAIN CASES

Act June 23, 1939, ch. 242, §§ 1, 2, 53 Stat. 853, 854, provided that:

“(SEC. 1) (a) The effective date of the following provisions of the Federal Food, Drug, and Cosmetic Act is hereby postponed until January 1, 1940: Sections 402(c) [342(c) of this title]; 403(e)(1) [343(e)(1) of this title]; 403(g), (h), (i), (j), and (k) [343(g) to (k) of this title]; 501(a), (4) [351(a)(4) of this title]; 502(b), (d), (e), (f), (g), and (h) [352(b), (d) to (h) of this title]; 601(e) [361(e) of this title]; and 602(b) [362(b) of this title].

“(b) The Secretary of Agriculture shall promulgate regulations further postponing to July 1, 1940[,] the effective date of the provisions of sections 403(e)(1) [343(e)(1) of this title]; 403(g), (h), (i), (j), and (k) [343(g) to (k)]; 502(b), (d), (e), (f), (g), and (h) [352(b), (d) to (h) of this title]; and 602(b) [362(b) of this title] of such Act with respect to lithographed labeling which was manufactured prior to February 1, 1939, and to containers bearing labeling which, prior to February 1, 1939, was lithographed, etched, stamped, pressed, printed, fused or blown on or in such containers, where compliance with such provisions would be unduly burdensome by reason of causing the loss of valuable stocks of such labeling or containers, and where such postponement would not prevent the public interest being adequately served: Provided, That in no case shall such regulations apply to labeling which would not have complied with